Literature DB >> 25197353

Effects of transforming growth factor-β2 on myocilin expression and secretion in human primary cultured trabecular meshwork cells.

Yuyu Wu1, Wanzhu Chen1, Maosheng Guo1, Qin He1, Yan Hu1.   

Abstract

High intraocular pressure (IOP) is a risk factor for primary open-angle glaucoma (POAG). The trabecular meshwork (TM), a reticular tissue in the outflow passage of the aqueous humor (AH), is a major contributor to intraocular outflow resistance. High levels of myocilin (MYOC), which is expressed in the TM, are associated with high IOP. Furthermore, transforming growth factor-β2 (TGF-β2) concentrations in human AH are significantly elevated in POAG patients. This study was designed to investigate the effects of TGF-β2 on MYOC expression and secretion in human primary cultured TM cells. Primary cultured human TM cells were treated with 0 (control group), 1, 10, and 100 ng/mL TGF-β2 for 12, 24, or 48 h. MYOC mRNA and protein expressions in TM cells and protein secretion in conditioned media were analyzed by semi-quantitative RT-PCR, Western blotting, and enzyme-linked immunosorbent assays (ELISA), respectively. TM cells treated with 1, 10, and, 100 ng/mL TGF-β2 for 48 h showed higher MYOC mRNA and protein expressions than those in the control group (0 ng/mL TGF-β2) (all P < 0.05). Treatment with TGF-β2 for 48 h also induced MYOC secretion in conditioned media in a dose-dependent manner (0 ng/mL: 7.107±1.163 pg/ml; 1 ng/mL: 7.879±1.894 pg/ml; 10 ng/mL: 8.063±1.181 pg/ml; 100 ng/mL: 8.902±0.699 pg/ml; all P < 0.05). In Conclusion, TGF-β2 induced MYOC expression and secretion in human primary cultured TM cells. Further investigations are required to confirm the involvement of these two factors in POAG pathogenesis.

Entities:  

Keywords:  Primary cell culture; glaucoma; myocilin; trabecular meshwork cells; transforming growth factor-beta 2

Mesh:

Substances:

Year:  2014        PMID: 25197353      PMCID: PMC4152043     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  51 in total

1.  The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration.The AGIS Investigators.

Authors: 
Journal:  Am J Ophthalmol       Date:  2000-10       Impact factor: 5.258

2.  Recombinant TIGR/MYOC increases outflow resistance in the human anterior segment.

Authors:  M P Fautsch; C K Bahler; D J Jewison; D H Johnson
Journal:  Invest Ophthalmol Vis Sci       Date:  2000-12       Impact factor: 4.799

3.  Nutritional, lifestyle and environmental factors in ocular hypertension and primary open-angle glaucoma: an exploratory case-control study.

Authors:  Jean-Paul Renard; Jean-François Rouland; Alain Bron; Eric Sellem; Jean-Philippe Nordmann; Christophe Baudouin; Philippe Denis; Max Villain; Gilles Chaine; Joseph Colin; Gérard de Pouvourville; Sybille Pinchinat; Nicholas Moore; Madina Estephan; Cécile Delcourt
Journal:  Acta Ophthalmol       Date:  2012-03-06       Impact factor: 3.761

4.  Ultrastructural localization of myocilin in human trabecular meshwork cells and tissues.

Authors:  J Ueda; K K Wentz-Hunter; E L Cheng; T Fukuchi; H Abe; B Y Yue
Journal:  J Histochem Cytochem       Date:  2000-10       Impact factor: 2.479

Review 5.  Myocilin and glaucoma: A TIGR by the tail?

Authors:  D H Johnson
Journal:  Arch Ophthalmol       Date:  2000-07

6.  Connective tissue growth factor causes glaucoma by modifying the actin cytoskeleton of the trabecular meshwork.

Authors:  Benjamin Junglas; Sabrina Kuespert; Amin A Seleem; Tobias Struller; Sabrina Ullmann; Michael Bösl; Anja Bosserhoff; Josef Köstler; Ralf Wagner; Ernst R Tamm; Rudolf Fuchshofer
Journal:  Am J Pathol       Date:  2012-04-26       Impact factor: 4.307

Review 7.  The role of transforming growth factor β in glaucoma and the therapeutic implications.

Authors:  Mark A Prendes; Alon Harris; Barbara M Wirostko; Austin L Gerber; Brent Siesky
Journal:  Br J Ophthalmol       Date:  2013-01-15       Impact factor: 4.638

8.  The glaucoma-associated olfactomedin domain of myocilin is a novel calcium binding protein.

Authors:  Rebecca K Donegan; Shannon E Hill; Katherine C Turnage; Susan D Orwig; Raquel L Lieberman
Journal:  J Biol Chem       Date:  2012-11-05       Impact factor: 5.157

9.  Hyaluronic acid increases MMP-2 and MMP-9 expressions in cultured trabecular meshwork cells from patients with primary open-angle glaucoma.

Authors:  Mao-Sheng Guo; Yu-Yu Wu; Zong-Bao Liang
Journal:  Mol Vis       Date:  2012-05-04       Impact factor: 2.367

10.  A role for myocilin in receptor-mediated endocytosis.

Authors:  Brian S McKay; Nicole R Congrove; Adiv A Johnson; W Michael Dismuke; Trent J Bowen; W Daniel Stamer
Journal:  PLoS One       Date:  2013-12-18       Impact factor: 3.240

View more
  4 in total

1.  Increased Complement-Associated Inflammation in Cytomegalovirus-Positive Hypertensive Anterior Uveitis Patients Based on the Aqueous Humor Proteomics Analysis.

Authors:  Jin A Choi; Hyun-Hee Ju; Jiyoung Lee; Ju-Eun Kim; Soon-Young Paik; Nikolai P Skiba; Ponugoti Vasantha Rao
Journal:  J Clin Med       Date:  2022-04-22       Impact factor: 4.964

2.  Pro-fibrotic pathway activation in trabecular meshwork and lamina cribrosa is the main driving force of glaucoma.

Authors:  Alex Zhavoronkov; Evgeny Izumchenko; Riya R Kanherkar; Mahder Teka; Charles Cantor; Kebreten Manaye; David Sidransky; Michael D West; Eugene Makarev; Antonei Benjamin Csoka
Journal:  Cell Cycle       Date:  2016-06-17       Impact factor: 4.534

Review 3.  Physiological function of myocilin and its role in the pathogenesis of glaucoma in the trabecular meshwork (Review).

Authors:  Hongwei Wang; Mingzhe Li; Zhenzhen Zhang; Haifeng Xue; Xing Chen; Yong Ji
Journal:  Int J Mol Med       Date:  2018-11-20       Impact factor: 4.101

4.  Cross-talk between MYOC p. Y437H mutation and TGF-β2 in the pathology of glaucoma.

Authors:  Yang Yang; Al Sabri Waled Abdulghani Abdulatef; LuSi Zhang; Haibo Jiang; Zhou Zeng; Haibo Li; Xiaobo Xia
Journal:  Int J Med Sci       Date:  2020-04-27       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.